V-INTERVENTION
Trial Overview
Official Title
Evaluation of inclisiran versus placebo for the prevention of major adverse cardiovascular and limb events in patients undergoing percutaneous coronary intervention or peripheral endovascular intervention.
Study Purpose
The purpose is to demonstrate superiority of inclisiran (LEQVIO) compared to placebo on lowering total (first and subsequent) major adverse cardiovascular and limb events after coronary or peripheral endovascular revascularization.
Diagnosis
Coronary Artery Disease (CAD) Peripheral Artery Disease (PAD)Eligibility
Evaluation of inclisiran versus placebo for the prevention of major adverse cardiovascular and limb events in patients undergoing percutaneous coronary intervention or peripheral endovascular intervention
Intervention
Inclisiran (LEQVIO)
For more information, visit clinicaltrials.gov.
Key Participation Requirements
Trial Location(s)
Gender
All
Age
19 and older
Enrollment Status
Recruiting
Phase
Phase IV
Methodist Health System Trial Code
NCT06909565